Literature DB >> 26071757

DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.

Tereza Vaclová1, Gonzalo Gómez-López, Fernando Setién, José María García Bueno, José Antonio Macías, Alicia Barroso, Miguel Urioste, Manel Esteller, Javier Benítez, Ana Osorio.   

Abstract

BRCA1 germline mutations increase the lifetime risk of developing breast and ovarian cancers. However, taking into account the differences in disease manifestation among mutation carriers, it is probable that different BRCA1 mutations have distinct haploinsufficiency effects and lead to the formation of different phenotypes. Using lymphoblastoid cell lines derived from heterozygous BRCA1 mutation carriers and non-carriers, we investigated the haploinsufficiency effects of various mutation types using qPCR, immunofluorescence, and microarray technology. Lymphoblastoid cell lines carrying a truncating mutation showed significantly lower BRCA1 mRNA and protein levels and higher levels of gamma-H2AX than control cells or those harboring a missense mutation, indicating greater spontaneous DNA damage. Cells carrying either BRCA1 mutation type showed impaired RAD51 foci formation, suggesting defective repair in mutated cells. Moreover, compared to controls, cell lines carrying missense mutations displayed a more distinct expression profile than cells with truncating mutations, which is consistent with different mutations giving rise to distinct phenotypes. Alterations in the immune response pathway in cells harboring missense mutations point to possible mechanisms of breast cancer initiation in carriers of these mutations. Our findings offer insight into how various heterozygous mutations in BRCA1 could lead to impairment of BRCA1 function and provide strong evidence of haploinsufficiency in BRCA1 mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26071757     DOI: 10.1007/s10549-015-3459-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

1.  Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.

Authors:  Yue Luo; Hui Wang; Xipeng Zhao; Chao Dong; Fengmei Zhang; Gang Guo; Gongshe Guo; Xiaowei Wang; Simon N Powell; Zhihui Feng
Journal:  Toxicol Res (Camb)       Date:  2016-02-18       Impact factor: 3.524

2.  Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.

Authors:  Tereza Vaclová; Nicholas T Woods; Diego Megías; Sergio Gomez-Lopez; Fernando Setién; José María García Bueno; José Antonio Macías; Alicia Barroso; Miguel Urioste; Manel Esteller; Alvaro N A Monteiro; Javier Benítez; Ana Osorio
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

3.  The fate of BRCA1-related germline mutations in triple-negative breast tumors.

Authors:  Vassiliki Kotoula; Florentia Fostira; Kyriaki Papadopoulou; Paraskevi Apostolou; Eleftheria Tsolaki; Georgios Lazaridis; Kyriaki Manoussou; Flora Zagouri; Dimitrios Pectasides; Ioannis Vlachos; Ioannis Tikas; Sotiris Lakis; Irene Konstantopoulou; George Pentheroudakis; Helen Gogas; Pavlos Papakostas; Christos Christodoulou; Dimitrios Bafaloukos; Evangelia Razis; Vasilios Karavasilis; Christina Bamias; Drakoulis Yannoukakos; George Fountzilas
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

4.  Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.

Authors:  Hiromi Tanaka; Elizabeth A Phipps; Ting Wei; Xi Wu; Chirayu Goswami; Yunlong Liu; George W Sledge; Lida Mina; Brittney-Shea Herbert
Journal:  Mol Carcinog       Date:  2018-01-05       Impact factor: 4.784

5.  Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.

Authors:  Rania Chehade; Rachael Pettapiece-Phillips; Leonardo Salmena; Max Kotlyar; Igor Jurisica; Steven A Narod; Mohammad R Akbari; Joanne Kotsopoulos
Journal:  Breast Cancer Res       Date:  2016-08-17       Impact factor: 6.466

6.  Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm.

Authors:  Jeroen Vierstraete; Andy Willaert; Petra Vermassen; Paul J Coucke; Anne Vral; Kathleen B M Claes
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

7.  Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers.

Authors:  Carlos Benitez-Buelga; Tereza Vaclová; Sofia Ferreira; Miguel Urioste; Lucia Inglada-Perez; Nora Soberón; Maria A Blasco; Ana Osorio; Javier Benitez
Journal:  Oncotarget       Date:  2016-05-03

8.  Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.

Authors:  Annelot Baert; Julie Depuydt; Tom Van Maerken; Bruce Poppe; Fransiska Malfait; Katrien Storm; Jenneke van den Ende; Tim Van Damme; Sylvia De Nobele; Gianpaolo Perletti; Kim De Leeneer; Kathleen B M Claes; Anne Vral
Journal:  Breast Cancer Res       Date:  2016-05-17       Impact factor: 6.466

9.  Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers.

Authors:  Carlos Benítez-Buelga; Juan Miguel Baquero; Tereza Vaclova; Victoria Fernández; Paloma Martín; Lucia Inglada-Perez; Miguel Urioste; Ana Osorio; Javier Benítez
Journal:  Oncotarget       Date:  2017-11-23

10.  Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families.

Authors:  Marie-Christine Pouliot; Charu Kothari; Charles Joly-Beauparlant; Yvan Labrie; Geneviève Ouellette; Jacques Simard; Arnaud Droit; Francine Durocher
Journal:  Oncotarget       Date:  2017-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.